title: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.
abstract: OBJECTIVE
  To determine the effectiveness of carcinoembryonic antigen (CEA) monitoring in detecting surgically curable recurrence of colon cancer.
  
  
  METHODS
  Clinical data were collected from a national surgical adjuvant trial in which CEA monitoring was elective.
  
  
  METHODS
  Cancer centers, universities, and community clinics.
  
  
  METHODS
  A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring.
  
  
  METHODS
  Sensitivity and specificity of CEA testing for cancer recurrence and CEA-motivated diagnostic and surgical interventions and their end results.
  
  
  RESULTS
  Among 417 monitored patients with recurrence, 59% had a preceding elevation of CEA concentration. Sixteen percent of 600 patients without recurrence showed a false-positive test result. Carcinoembryonic antigen testing was most sensitive for hepatic or retroperitoneal metastasis and relatively insensitive for local, pulmonary, or peritoneal involvement. Surgical explorations were performed in 115 patients with CEA elevations, and 47 recurrences, usually hepatic, were resected with curative intent. On the other hand, 38 patients with normal CEA concentrations and 23 patients not monitored also underwent such resections--usually for pulmonary or local recurrence. Of all CEA-monitored patients, 2.3% are alive and disease free more than 1 year after salvage surgery (2.9% of those with CEA elevations and 1.9% of those with no elevations). Of patients with no CEA monitoring, 2.0% are also alive and disease free more than 1 year after salvage surgery.
  
  
  CONCLUSIONS
  Cancer cures attributable to CEA monitoring are, at best, infrequent. It is questionable whether this small gain justifies the substantial cost in dollars and physical and emotional stress that this intervention may cause for patients.
authors.affiliation: Mayo Clinic Rochester, MN 55905.
authors.forename: C G
authors.initials: CG
authors.lastname: Moertel
authors.forename: T R
authors.initials: TR
authors.lastname: Fleming
authors.forename: J S
authors.initials: JS
authors.lastname: Macdonald
authors.forename: D G
authors.initials: DG
authors.lastname: Haller
authors.forename: J A
authors.initials: JA
authors.lastname: Laurie
authors.forename: C
authors.initials: C
authors.lastname: Tangen
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis* / Q000191:economics; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000191:economics; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D003362:Cost-Benefit Analysis; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000517:prevention & control* / Q000601:surgery; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D007978:Levamisole; D005472:Fluorouracil